Top
image credit: Adobe Stock

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

September 20, 2022

Category:

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course of their lifetime.

Lupkynis (voclosporin) has been cleared by the European Commission for use in combination with immunosuppressant mycophenolate mofetil (MMF) for adult patients with moderate to severe (class III to V) LN.

Read More on Pharmaphorum